Clinical trial
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for…
NCT00183898 · University of Southern California, Other · Unknown status
Key facts
| NCT number | NCT00183898 |
|---|---|
| Title | Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer |
| Official title | Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Sanofi Industry Roche Global Development Bristol-Myers Squibb |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Esophageal Cancer |
| Intervention type | Drug |
| Interventions | oxaliplatin, capecitabine |
| Enrollment | 75 |
| Start date | Dec 28, 2004 |
| Primary completion | Feb 4, 2013 |
| Completion | Dec 28, 2019 |
| First posted | Sep 16, 2005 |
| Last update posted | May 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: